ImmunityBio Reports Strong Q1 2026 Revenue Growth
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy IBRX?
Source: Newsfilter
ImmunityBio's stock rose by 5.01% as it crossed above the 5-day SMA, reflecting positive investor sentiment following the company's strong revenue report.
The company reported preliminary net product revenue of approximately $44.2 million for Q1 2026, a remarkable 168% year-over-year increase, driven by the continued adoption of ANKTIVA® among U.S. urologists. Additionally, the full-year 2025 net product revenue reached $113 million, showcasing a 700% increase over 2024, which highlights the company's successful commercialization efforts. The expansion of ANKTIVA's approval across five regulatory jurisdictions covering about 34 countries further strengthens its market position and sets the stage for future growth.
This strong performance indicates ImmunityBio's potential for continued growth in the competitive biopharmaceutical market, especially with the ongoing clinical trial progress for ANKTIVA.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IBRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IBRX
Wall Street analysts forecast IBRX stock price to fall
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 7.480
Low
5.00
Averages
7.33
High
9.00
Current: 7.480
Low
5.00
Averages
7.33
High
9.00
About IBRX
Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its applied science and platforms to treat cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies to reduce or eliminate the need for standard high-dose chemotherapy. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins, vaccine vectors, and cell therapies. Its biologic commercial product candidate, Anktiva, is an IL-15 superagonist antibody-cytokine fusion protein.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Reminder of ImmunityBio Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased ImmunityBio securities between January 19 and March 24, 2026, that the deadline to apply as lead plaintiff is May 26, allowing potential compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that executives made false statements regarding Anktiva's capabilities during the Class Period, resulting in investor losses when the truth emerged, highlighting significant governance and disclosure issues within the company.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest settlement against a Chinese company, as well as being ranked first for the number of settlements in 2017, indicating its expertise and success in this field.
- Investor Guidance: Investors are advised to select counsel with a proven track record rather than firms that merely act as intermediaries, ensuring they receive the best representation and support in litigation.
See More
ImmunityBio Faces Securities Class Action Lawsuit
- Lawsuit Background: ImmunityBio is facing a securities class action lawsuit due to misleading statements made by its Chief Scientific Officer regarding Anktiva's efficacy during a podcast, involving investors from January 19 to March 24, 2026, highlighting significant risks in the company's information disclosure practices.
- FDA Warning Impact: The FDA issued a warning letter to ImmunityBio, indicating that its promotional materials misrepresented Anktiva's efficacy, resulting in a more than 21% drop in stock price on March 24, 2026, erasing nearly $2 billion in market capitalization, demonstrating the direct impact of regulatory risks on shareholder confidence.
- Investor Rights Protection: Hagens Berman is investigating whether ImmunityBio intentionally misled investors, urging those who suffered significant losses to submit claims, reflecting the market's heightened concern over the company's transparency and compliance.
- Public Health Risks: The FDA emphasized that ImmunityBio's promotional materials could pose a public health threat due to misleading claims about Anktiva's efficacy, further underscoring the company's accountability issues in market promotion.
See More
Reminder of ImmunityBio Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased ImmunityBio (NASDAQ: IBRX) securities between January 19 and March 24, 2026, that they must apply to be lead plaintiff by May 26, 2026, or risk losing representation in the class action.
- Fee Arrangement: Investors participating in the class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, allowing them to seek compensation without financial burden.
- Lawsuit Background: The lawsuit alleges that executives at ImmunityBio made false or misleading statements during the class period, resulting in investor losses when the true information was revealed, indicating significant issues with the company's business and prospects.
- Law Firm's Strength: Rosen Law Firm is recognized for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, showcasing its expertise and resource advantages in handling similar cases.
See More
Multiple Companies Face Class Action Lawsuits
- Super Micro Lawsuit: Super Micro Computer, Inc. (NASDAQ:SMCI) faces a class action for failing to disclose that a significant portion of its server sales were to Chinese companies, violating U.S. export laws during the class period from April 30, 2024, to March 12, 2026, potentially damaging its reputation and future sales prospects.
- ImmunityBio Lawsuit: ImmunityBio, Inc. (NASDAQ:IBRX) is accused of overstating Anktiva's capabilities during the class period from January 19, 2026, to March 24, 2026, which could severely undermine investor confidence in the company's prospects and affect its market performance and financing capabilities.
- Pinterest Lawsuit: Pinterest, Inc. (NYSE:PINS) faces a class action for not disclosing risks of declining advertising revenues during the class period from February 7, 2025, to February 12, 2026, which may lead to imminent restructuring and impact its advertising strategy and market share.
- Legal Consultation Services: The Law Offices of Frank R. Cruz remind investors of their rights in these class actions, emphasizing their commitment to investor protection, which may enhance their reputation in the legal services market.
See More
ImmunityBio Faces Class Action Lawsuit
- Class Action Initiated: Bragar Eagel & Squire, P.C. has announced a class action lawsuit against ImmunityBio for investors who purchased securities between January 19, 2026, and March 24, 2026, indicating significant legal risks that may undermine shareholder confidence.
- Allegations of False Statements: The lawsuit alleges that ImmunityBio's executive Patrick Soon-Shiong materially overstated Anktiva's capabilities, resulting in misleading statements about the company's business and prospects, which could lead to investor losses.
- Investor Rights Protection: Investors must apply by May 26, 2026, to be appointed as lead plaintiff in the lawsuit, highlighting the urgency of the legal process and its potential impact on investor decisions and future legal actions.
- Law Firm Background: Bragar Eagel & Squire, P.C. is a nationally recognized law firm specializing in shareholder rights and securities litigation, indicating the firm's capability to handle complex legal cases, which may influence the outcome of the lawsuit.
See More
Faruqi & Faruqi Investigates ImmunityBio Securities Litigation
- Legal Investigation: Faruq & Faruqi LLP is investigating potential claims against ImmunityBio, involving investors who purchased securities between January 19, 2026, and March 24, 2026, indicating the company faces legal risks that could impact its stock performance.
- Investor Contact Information: Securities Litigation Partner Josh Wilson encourages affected investors to contact him directly, providing phone numbers and extension, demonstrating the firm's commitment to investor rights and potentially attracting more victims to participate in the lawsuit.
- Lawsuit Deadline: Investors must apply to become lead plaintiffs by May 26, 2026, highlighting the urgency of the lawsuit, which may prompt more investors to take action before this date, affecting the company's reputation and market confidence.
- Securities Class Action: The federal securities class action against ImmunityBio reflects investor concerns about the company's financial health, potentially leading to greater legal and financial pressures on the company, impacting its future fundraising capabilities and market performance.
See More
Reminder of ImmunityBio Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased ImmunityBio securities between January 19 and March 24, 2026, that the deadline to apply as lead plaintiff is May 26, allowing potential compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that executives made false statements regarding Anktiva's capabilities during the Class Period, resulting in investor losses when the truth emerged, highlighting significant governance and disclosure issues within the company.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest settlement against a Chinese company, as well as being ranked first for the number of settlements in 2017, indicating its expertise and success in this field.
- Investor Guidance: Investors are advised to select counsel with a proven track record rather than firms that merely act as intermediaries, ensuring they receive the best representation and support in litigation.
See More
ImmunityBio Faces Securities Class Action Lawsuit
- Lawsuit Background: ImmunityBio is facing a securities class action lawsuit due to misleading statements made by its Chief Scientific Officer regarding Anktiva's efficacy during a podcast, involving investors from January 19 to March 24, 2026, highlighting significant risks in the company's information disclosure practices.
- FDA Warning Impact: The FDA issued a warning letter to ImmunityBio, indicating that its promotional materials misrepresented Anktiva's efficacy, resulting in a more than 21% drop in stock price on March 24, 2026, erasing nearly $2 billion in market capitalization, demonstrating the direct impact of regulatory risks on shareholder confidence.
- Investor Rights Protection: Hagens Berman is investigating whether ImmunityBio intentionally misled investors, urging those who suffered significant losses to submit claims, reflecting the market's heightened concern over the company's transparency and compliance.
- Public Health Risks: The FDA emphasized that ImmunityBio's promotional materials could pose a public health threat due to misleading claims about Anktiva's efficacy, further underscoring the company's accountability issues in market promotion.
See More
Reminder of ImmunityBio Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased ImmunityBio (NASDAQ: IBRX) securities between January 19 and March 24, 2026, that they must apply to be lead plaintiff by May 26, 2026, or risk losing representation in the class action.
- Fee Arrangement: Investors participating in the class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, allowing them to seek compensation without financial burden.
- Lawsuit Background: The lawsuit alleges that executives at ImmunityBio made false or misleading statements during the class period, resulting in investor losses when the true information was revealed, indicating significant issues with the company's business and prospects.
- Law Firm's Strength: Rosen Law Firm is recognized for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, showcasing its expertise and resource advantages in handling similar cases.
See More
Multiple Companies Face Class Action Lawsuits
- Super Micro Lawsuit: Super Micro Computer, Inc. (NASDAQ:SMCI) faces a class action for failing to disclose that a significant portion of its server sales were to Chinese companies, violating U.S. export laws during the class period from April 30, 2024, to March 12, 2026, potentially damaging its reputation and future sales prospects.
- ImmunityBio Lawsuit: ImmunityBio, Inc. (NASDAQ:IBRX) is accused of overstating Anktiva's capabilities during the class period from January 19, 2026, to March 24, 2026, which could severely undermine investor confidence in the company's prospects and affect its market performance and financing capabilities.
- Pinterest Lawsuit: Pinterest, Inc. (NYSE:PINS) faces a class action for not disclosing risks of declining advertising revenues during the class period from February 7, 2025, to February 12, 2026, which may lead to imminent restructuring and impact its advertising strategy and market share.
- Legal Consultation Services: The Law Offices of Frank R. Cruz remind investors of their rights in these class actions, emphasizing their commitment to investor protection, which may enhance their reputation in the legal services market.
See More
ImmunityBio Faces Class Action Lawsuit
- Class Action Initiated: Bragar Eagel & Squire, P.C. has announced a class action lawsuit against ImmunityBio for investors who purchased securities between January 19, 2026, and March 24, 2026, indicating significant legal risks that may undermine shareholder confidence.
- Allegations of False Statements: The lawsuit alleges that ImmunityBio's executive Patrick Soon-Shiong materially overstated Anktiva's capabilities, resulting in misleading statements about the company's business and prospects, which could lead to investor losses.
- Investor Rights Protection: Investors must apply by May 26, 2026, to be appointed as lead plaintiff in the lawsuit, highlighting the urgency of the legal process and its potential impact on investor decisions and future legal actions.
- Law Firm Background: Bragar Eagel & Squire, P.C. is a nationally recognized law firm specializing in shareholder rights and securities litigation, indicating the firm's capability to handle complex legal cases, which may influence the outcome of the lawsuit.
See More
Faruqi & Faruqi Investigates ImmunityBio Securities Litigation
- Legal Investigation: Faruq & Faruqi LLP is investigating potential claims against ImmunityBio, involving investors who purchased securities between January 19, 2026, and March 24, 2026, indicating the company faces legal risks that could impact its stock performance.
- Investor Contact Information: Securities Litigation Partner Josh Wilson encourages affected investors to contact him directly, providing phone numbers and extension, demonstrating the firm's commitment to investor rights and potentially attracting more victims to participate in the lawsuit.
- Lawsuit Deadline: Investors must apply to become lead plaintiffs by May 26, 2026, highlighting the urgency of the lawsuit, which may prompt more investors to take action before this date, affecting the company's reputation and market confidence.
- Securities Class Action: The federal securities class action against ImmunityBio reflects investor concerns about the company's financial health, potentially leading to greater legal and financial pressures on the company, impacting its future fundraising capabilities and market performance.
See More
